57 citations
,
July 2016 in “The Journal of Sexual Medicine” 5α-reductase inhibitors increase the risk of sexual dysfunction, especially in men with enlarged prostate.
Finasteride and dutasteride are not recommended for feminizing therapy due to limited effectiveness and potential risks.
5α-reductase inhibitors effectively treat enlarged prostate and hair loss but require careful use due to possible side effects.
19 citations
,
October 2018 in “PLOS ONE” 5 alpha-reductase inhibitors can slightly improve symptoms of enlarged prostate but have a high risk of sexual side effects.
July 2025 in “Saudi Journal of Medicine and Public Health” 5α-reductase inhibitors effectively treat enlarged prostate and hair loss but require careful use due to possible side effects.
5-ARI therapy may help prevent prostate cancer progression.
These medications for BPH have known risks and may have new side effects.
December 2012 in “Canadian Urological Association Journal” 5-alpha reductase inhibitors help treat prostate issues in aging men, but their role in cancer prevention is debated.
These medications for BPH have known risks and may have new side effects.
4 citations
,
August 2010 in “Acta Biologica Hungarica” New steroidal compounds moderately block an enzyme related to testosterone conversion, less effectively than finasteride.
1 citations
,
February 2022 in “The Journal of Urology” Certain drugs like Dutasteride and Finasteride might help fight SARS-CoV-2 by increasing levels of a steroid called DHEA, which can protect the heart and increase nitric oxide to counteract the virus.
5 citations
,
January 2001 in “Advances in protein chemistry” 5α-reductase inhibitors help treat disorders caused by DHT and have potential for future therapies.
7 citations
,
January 2025 in “Journal of Experimental & Clinical Cancer Research” PRMT5 inhibitors effectively fight adenoid cystic carcinoma in salivary glands.
Canadian lawsuits involving 5-alpha-reductase inhibitors are related to persistent erectile dysfunction side effects, with no judgments against companies yet.
January 2016 in “Archivio italiano di urologia, andrologia” The document concludes that the risk of sexual side effects from 5-alpha-reductase inhibitors is low and often temporary, but more research is needed on potential permanent effects.
6 citations
,
September 2024 in “Journal of the American Academy of Dermatology” Oral 5-alpha reductase inhibitors do not increase breast cancer or benign breast disorder risk in women.
8 citations
,
June 2017 in “Steroids” New chemical compounds were made that effectively block an enzyme linked to prostate growth.
May 2023 in “Acta Oncologica” 5α-reductase inhibitors do not improve survival in oesophageal and gastric cancer patients.
47 citations
,
January 2003 in “Current opinion in urology” A new drug, dutasteride, is at least as effective as the older drug, finasteride, for treating enlarged prostate and may have additional uses.
18 citations
,
June 2017 in “Journal of the neurological sciences” Using 5 alpha reductase inhibitors may increase dementia risk in the first two years.
July 2025 in “American Journal on Addictions” Using 5-alpha reductase inhibitors may lower the risk of opioid addiction in men taking opioids.
August 2011 in “Der Urologe” 5α-reductase inhibitors lower overall prostate cancer risk but not high-grade cancer risk; longer-term screening and new treatments show promise.
January 2007 in “日本看護学会抄録集 成人看護1” Certain amino acids in 5AR1 and 5AR2 are crucial for binding and resistance to Finasteride.
January 2006 in “Zhongguo yaofang” The market for these drugs is expected to grow.
January 2018 in “Surgical and Cosmetic Dermatology” Finasteride and dutasteride are effective for male hair loss and enlarged prostate but may cause reversible sexual side effects.
July 2024 in “Age and Ageing” Men taking dutasteride may have a higher risk of age-related macular degeneration.
March 2026 in “Journal of Clinical Oncology” Using 5-α-reductase inhibitors before treatment improves outcomes for patients with metastatic renal cell carcinoma.
4 citations
,
September 2022 in “Experimental and Сlinical Urology” 5-alpha reductase inhibitors help with benign prostatic hyperplasia but don't cure it, and more research is needed.
129 citations
,
January 2004 in “Journal of medicinal chemistry” Researchers developed new compounds that target the androgen receptor effectively with fewer side effects.
October 2010 in “Journal of Men's Health” The conclusion is that doctors should be careful when prescribing 5α-reductase inhibitors due to possible serious side effects, and they should discuss these risks with patients.